Literature DB >> 16109616

Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection.

Jakub Svoboda1, Charalambos Andreadis, Lisa H Downs, Wallace T Miller, Donald E Tsai, Stephen J Schuster.   

Abstract

We describe a patient with chronic hepatitis C virus (HCV) infection who presented with extranodal (right salivary gland and bone marrow) marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). Within a year, the lymphoma progressed to involve peripheral lymph nodes and the liver. After treatment of HCV with peginterferon and ribavirin, he achieved complete radiographic response and remains in remission two years later. This is an example of a patient in whom treatment of HCV infection led to regression of non-splenic, extranodal marginal zone lymphoma. It suggests that HCV testing and treatment should be considered in all patients with marginal zone lymphomas, including non-splenic types.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109616     DOI: 10.1080/104281905001028289

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Splenic marginal zone lymphoma masquerading as cirrhotic hypersplenism for seven years.

Authors:  John Alfred Carr
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Authors: 
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

3.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

Review 4.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

5.  Hepatitis C virus infection and locally advanced splenic marginal zone lymphoma.

Authors:  Bartlomiej Szynglarewicz; Rafał Matkowski; Zbigniew Smorag; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

6.  Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.

Authors:  Lindsay M Morton; Ola Landgren; Nilanjan Chatterjee; David Castenson; Ruth Parsons; Robert N Hoover; Eric A Engels
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

7.  Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA.

Authors:  Iman Gouda; Ola Nada; Sameera Ezzat; Mai Eldaly; Christopher Loffredo; Clive Taylor; Mohamed Abdel-Hamid
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-01

Review 8.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

Review 9.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.